You got me for a day.
Tomorrow though is a different story. I have many things to do I must do.
Debate me not downvote me.
There is some logic to the tax brigade.
I fail to find it but they insist it is true.
I had this conversation with my mother yesterday, it went like this.
"Me, when a government can self sustain. As they have been going for hundreds of years, and any business worth it's weight in gold can self sustain without tax. Then I will vote for them."
She replied thus "That would equal rampant inflation and no GDP."
I replied " How much did you pay for your first house?"
She replied "£1,750.00 in 1960"
I asked "how much did you pay for your last house?"
She replied "£175,000.00"
And then the cognitive dissonance kicked in and she put the phone down on me!
And this folks is where we are at.
Facts matter not.
Just people choosing to believe shite "because"
It must be oh so comforting not liking reality and living in some dream.
When people play a game, you got to play the same game.
So Okay here we go on germ theory.
The New Nuremberg Trials 2021 – Please Share This Info!
Posted on May 3, 2021 AuthorQ Comments Offon The New Nuremberg Trials 2021 – Please Share this info!
PLEASE SUPPORT A FREE AND INDEPENDENT PRESS!PLEASE SUPPORT A FREE AND INDEPENDENT PRESS!
The New Nuremberg Trials 2021
A team of over 1,000 lawyers and over 10,000 medical experts led by Dr. Reiner Fuellmich have begun legal proceedings against the CDC, WHO & the Davos Group for crimes against humanity. Fuellmich and his team present the faulty PCR test and the order for doctors to label any comorbidity death as a Covid death as fraud. The PCR test was never designed to detect pathogens and is 100% faulty at 35 cycles. All the PCR tests overseen by the CDC are set at 37 to 45 cycles. The CDC admits that any tests over 28 cycles are not admissible for a positive reliable result. This alone invalidates over 90% of the alleged covid cases / ”infections” tracked by the use of this faulty test.
In addition to the flawed tests and fraudulent death certificates, the “experimental” vaccine itself is in violation of Article 32 of the Geneva Convention. Under Article 32 of the 1949 Geneva Convention IV, “mutilation and medical or scientific experiments not necessitated by the medical treatment of a protected person” are prohibited. According to Article 147, conducting biological experiments on protected persons is a grave breach of the Convention.
The “experimental” vaccine is in violation of all 10 of the Nuremberg Codes which carry the death penalty for those who seek to violate these International Laws.
The “vaccine” fails to meet the following five requirements to be considered a vaccine and is by definition a medical “experiment” and trial:
Provides immunity to the virus
This is a “leaky” gene therapy that does not provide immunity to Covid and claims to reduce symptoms yet double-vaccinated are now 60% of the patients requiring ER or ICU with covid infections.
Protects recipients from getting the virus
This gene-therapy does not provide immunity and double-vaccinated can still catch and spread the virus.
Reduces deaths from the virus infection
This gene-therapy does not reduce deaths from the infection. Double-Vaccinated infected with Covid have also died.
So here we go, let us play the same game.
And here we go using their trials and tribulations.
“In politics, stupidity is not a handicap,” Napoleon is reputed to have said more than two centuries ago. Boundless ignorance is also not a handicap, as Congress demonstrated last December by approving a 5593-page bill without reading it. Plenty of activists and editorial pages howled over the sloppy procedures propelling $2.3 trillion in new federal spending.
James Madison warned in the Federalist Papers in 1788 that “it will be of little avail to the people, that the laws are made by men of their own choice, if the laws be so voluminous that they cannot be read, or so incoherent that they cannot be understood.” Madison referred to the peril of excessive legislation; he may have never imagined that Congress would routinely enact thousand-page blockbusters without reading the text. But that is now standard procedure in Washington.
On the night of the day before Thanksgiving 1991, the House of Representatives approved a 1400-page highway bill — even though almost no member of the House had seen the bill and only one copy was available in the House chamber. Sen. David Boren (D-Okla.) observed at the time that congressional “bills are five times longer on the average than they were just as recently as 1970, with a far greater tendency to micromanage every area of government.” Conservatives were outraged, and a Republican Leadership Task Force proclaimed in 1993, “A bill that cannot survive a three-day scrutiny of its provisions is a bill that should not be enacted.”
When Bill Clinton railroaded a 972-page crime bill into law in 1994, Republicans saw the legislation only a few hours before the vote. That was irrelevant because Clinton proclaimed that it was “the will of God” that Congress speedily pass the bill. Clinton’s bill created dozens of new criminal offenses and opened a $10 billion subsidy spigot for local and state prison building that sent America’s incarceration rate skyrocketing in the late 1990s and early 2000s.
Republicans captured control of Congress in the 1994 elections. But that did not deter House Speaker Newt Gingrich and Clinton from jamming a 4000-page, 40-pound agreement down Congress’s throat in 1998. No one had a chance to read the bill before voting. Legendary “King of Pork” Sen. Robert Byrd (D-W.Va.) declared, “Only God knows what’s in this monstrosity.”
A bit more of them here.
Immunization with SARS Coronavirus Vaccines Leads to
Pulmonary Immunopathology on Challenge with the
Chien-Te Tseng1,2, Elena Sbrana1
, Naoko Iwata-Yoshikawa1,2, Patrick C. Newman1
, Tania Garron1
Robert L. Atmar3,4, Clarence J. Peters1,2, Robert B. Couch3,4*
1 Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America, 2 Center for Biodefense and
Emerging Disease, The University of Texas Medical Branch, Galveston, Texas, United States of America, 3 Department of Medicine, Baylor College of Medicine, Houston,
Texas, United States of America, 4 Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America
Background: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before
brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine
development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a viruslike-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologictype lung disease.
Design: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a
VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or
C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live
virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.
Results: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing
responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All
mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and
C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals
given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration,
confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil
Conclusions: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However,
challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to
SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
Citation: Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, et al. (2012) Immunization with SARS Coronavirus Vaccines Leads to Pulmonary
Immunopathology on Challenge with the SARS Virus. PLoS ONE 7(4): e35421. doi:10.1371/journal.pone.0035421
Editor: Stefan Poehlmann, German Primate Center, Germany
Received January 31, 2012; Accepted March 15, 2012; Published April 20, 2012
Copyright: 2012 Tseng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research performed by the authors and summarized in this report was supported by Public Health Service Contract NO1 AI 30039 from the National
Institute of Allergy and Infectious Diseases. The content of this publication does not necessarily reflect the views or policies of the Department of Health and
Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
- E-mail: [email protected]
Severe acute respiratory syndrome (SARS) emerged in
Guangdong, People’s Republic of China, in late 2002, and spread
to other countries in Asia and to Canada in the ensuing months
[1–3]. Infection control efforts brought the infection under control
by mid-2003 . More than 8000 cases, including almost 800
deaths, were reported during the outbreak period . Increasing
age and comorbidity were risk factors for severe disease and death
[5,6,7]. Since 2003, only sporadic cases have been reported;
however, the possibility that SARS outbreaks could reemerge
naturally or be deliberately released is a public health concern.
SARS is caused by a Coronavirus (SARS-CoV) [8,9]. Limited
data are available about the ecology of SARS-CoV, but bats are
thought to be the animal reservoir for the virus which may be
transmitted to small mammals with exposure to these small
animals as the source of human infections . The clinical
disease is similar to other severe acute respiratory infections,
including influenza; the SARS case definition includes clinical,
epidemiologic, and laboratory criteria [11,12]. A number of
therapeutic efforts were employed for the disease in Asia and in
Canada; however, no treatment of clear value was identified.
Animal models were developed using mice, hamsters, ferrets and
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35421
nonhuman primates, and efforts to identify useful treatments and
effective vaccines are ongoing.
Vaccine candidates for preventing SARS have been developed
by various groups and include inactivated whole virus, spike (S)
protein preparations, virus-like particles (VLPs), plasmid DNA and
a number of vectors containing genes for SARS-CoV proteins
[13–28]. Phase I studies in humans have been conducted with a
whole virus vaccine and a DNA vaccine [29–30].
An early concern for application of a SARS-CoV vaccine was
the experience with other coronavirus infections which induced
enhanced disease and immunopathology in animals when
challenged with infectious virus , a concern reinforced by
the report that animals given an alum adjuvanted SARS vaccine
and subsequently challenged with SARS-CoV exhibited an
immunopathologic lung reaction reminiscent of that described
for respiratory syncytial virus (RSV) in infants and in animal
models given RSV vaccine and challenged naturally (infants) or
artificially (animals) with RSV [32,33]. We and others described a
similar immunopathologic reaction in mice vaccinated with a
SARS-CoV vaccine and subsequently challenged with SARS-CoV
[18,20,21,28]. It has been proposed that the nucleocapsid protein
of SARS-CoV is the antigen to which the immunopathologic
reaction is directed [18,21]. Thus, concern for proceeding to
humans with candidate SARS-CoV vaccines emerged from these
The studies reported here were conducted to evaluate the safety,
immunogenicity, and efficacy of different SARS-CoV vaccines in a
murine model of SARS.
Materials and Methods
Tissue Cultures and Virus
Vero E6 tissue cultures [obtained from The American Type
Culture Collection (ATCC), CRL:1586] were grown in Dulbecco’s modified minimum essential medium (DMEM) supplemented
with penicillin (100 units/ml), streptomycin (100 mg/ml), 0.2%
sodium bicarbonate and 10% fetal bovine serum (FBS). The
Urbani strain of SARS-CoV was obtained from T.G. Ksiazek at
the Centers for Disease Control and Prevention (Atlanta, GA), and
a working stock of this virus was prepared by serially passaging a
portion of the seed virus three times (p3) in Vero E6 cultures. The
culture fluid from infected cells was clarified by low-speed
centrifugation, filtered through a 0.45 mm filter, aliquoted, and
stored at 280uC.
Four different SARS-CoV vaccines were evaluated in these
studies (Table 1). Two whole virus vaccines were evaluated; one
was prepared in Vero tissue cultures, zonal centrifuged for
purification, and double-inactivated with formalin and UV
irradiation, the DI vaccine (DIV); it was tested with and without
alum adjuvant . The other whole virus vaccine was prepared
in Vero cells, concentrated, purified, inactivated with beta
propiolactone and packaged with alum adjuvant (BPV) . A
recombinant DNA spike (S) protein vaccine (SV) was produced in
insect cells and purified by column chromatography was tested
with and without alum adjuvant . The fourth vaccine (the
VLP vaccine) was a virus-like particle vaccine prepared by us as
described previously; it contained the SARS-CoV spike protein (S)
and the Nucleocapsid (N), envelope (E) and membrane (M)
proteins from mouse hepatitis coronavirus (MHV) .
Six- to eight-week-old, female Balb/c and C57BL/6 mice
(Charles River Laboratory, Wilmington, MA), were housed in
cages covered with barrier filters in an approved biosafety level 3
animal facility maintained by the University of Texas Medical
Branch (UTMB) at Galveston, Texas. All of the experiments were
performed using experimental protocols approved by the Office of
Research Project Protections, Institutional Animal Care and Use
Committee (IACUC), University of Texas Medical Branch and
followed National Institutes of Health and United States
Department of Agriculture guidelines.
Three different experiments, performed for comparing different
vaccines, are reported here. Adjuvanted (alum) and nonadjuvanted (PBS) vaccines were obtained from the NIH/BEI
resource. Groups of mice (N = 12–13 per group) were administered various dosages of each vaccine intramuscularly (IM) on days
0 and 28; mice given only PBS, alum, trivalent inactivated
influenza vaccine or live SARS-CoV were included as controls in
various experiments. On day 56, five mice from each group were
sacrificed for assessing serum neutralizing antibody titers and lung
histopathology; the remaining seven or eight mice in each group
were challenged with 106
TCID50/60 ml of SARS-CoV intranasally (IN). Challenged mice were euthanized on day 58 for
determining virus quantity and preparing lung tissue sections for
Neutralizing Antibody Assays
Mice were anesthetized with isoflurane and then bled from the
retro-orbital sinus plexus. After heat inactivation at 56uC for
30 minutes, sera were stored at 280uC until tested. Assays for
virus-specific neutralizing antibodies were performed on serial 2-
fold diluted samples of each serum using 2% FBS-DMEM as the
diluent in 96-well tissue culture plates (Falcon 3072); the final
volume of the serially diluted samples in each well was 60 ml after
addition of 120 TCID50 of SARS-CoV in 60 ml into each well.
The beginning dilution of serum was 1:20. The dilutions were
incubated for 45–60 minutes at room temperature; then 100 ml of
each mixture was transferred into duplicate wells of confluent
Vero E6 cells in 96-well microtiter plates. After 72 hours of
incubation, when the virus control wells exhibited advanced virusinduced CPE, the neutralizing capacity of individual serum
samples were assessed by determining the presence or absence of
cytopathic effect (CPE). Neutralizing antibody titers were
expressed as the reciprocal of the last dilution of serum that
completely inhibited virus-induced CPE.
Collection and Processing of Lungs for Histology and
Two days post SARS-CoV challenge, mice were euthanized
and their lungs were removed. Lung lobes were placed in 10%
neutral buffered formalin for histological examination and
immunohistochemistry (IHC), as described previously [34,35].
For virus quantitation, the remaining tissue specimen was weighed
and frozen to 280uC. Thawed lung was homogenized in PBS/
10% FBS solution using the TissueLyser (Qiagen; Retsch, Haan,
Germany). The homogenates were centrifuged and SARS-CoV
titers in the clarified fluids were determined by serial dilution in
quadruplicate wells of Vero E6 cells in 96-well plates. Titers of
virus in lung homogenates were expressed as TCID50/g of lung
(log10); the minimal detectable level of virus was 1.6 to 2.6 log10
TCID50 as determined by lung size."
I said to my mother "there is only 1 thing in life that is a guarantee."
And that is death,
She said that and taxes.
I disagreed with the tax part hence the above conversation.
To my mind at least.
Any government that has been around for hundreds of years should be able to self sustain.
Would you buy shares in any company that can not?
Would you give me free money to tell you what to do and think?
Would you let me police you, and have armies to fight my wars for me in your name?
Debate me. Get your A game on!